CAMP4 Therapeutics Corporation

NasdaqGM CAMP

CAMP4 Therapeutics Corporation Price to Book Ratio (P/B) on January 14, 2025: -8.19

CAMP4 Therapeutics Corporation Price to Book Ratio (P/B) is -8.19 on January 14, 2025, a 14.02% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

CAMP4 Therapeutics Corporation 52-week high Price to Book Ratio (P/B) is -0.33 on June 12, 2024, which is 95.92% above the current Price to Book Ratio (P/B).
CAMP4 Therapeutics Corporation 52-week low Price to Book Ratio (P/B) is -25.71 on November 12, 2024, which is -213.90% below the current Price to Book Ratio (P/B).
CAMP4 Therapeutics Corporation average Price to Book Ratio (P/B) for the last 52 weeks is -9.93.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGM: CAMP

CAMP4 Therapeutics Corporation

CEO	Mr. Joshua Mandel-Brehm
IPO Date	Oct. 11, 2024
Location	United States
Headquarters	One Kendall Square Bldg 1400 West, 3rd Floor
Employees	58
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

Key trends

Past 5 years